Search results for "Therapeutics."

showing 10 items of 480 documents

Role of the progesterone receptor for paclitaxel resistance in primary breast cancer

2007

Paclitaxel plays an important role in the treatment of primary breast cancer. However, a substantial proportion of patients treated with paclitaxel does not appear to derive any benefit from this therapy. We performed a prospective study using tumour cells isolated from 50 primary breast carcinomas. Sensitivity of primary tumour cells to paclitaxel was determined in a clinically relevant range of concentrations (0.85-27.2 microg ml(-1) paclitaxel) using an ATP assay. Chemosensitivity data were used to study a possible association with immunohistochemically determined oestrogen and progesterone receptor (ER and PR) status, as well as histopathological parameters. Progesterone receptor (PR) m…

Cancer Researchmedicine.medical_specialtyReceptor StatusPaclitaxelmedicine.medical_treatmentBreast Neoplasmsprogesterone receptorchemistry.chemical_compoundBreast cancerInternal medicineProgesterone receptormedicineHumansRNA Messengerprimary tumour cellsChemotherapyBase SequenceDose-Response Relationship Drugbusiness.industryAntineoplastic AgentsPhytogenic/therapeutic use/Base Sequence/Breast Neoplasms/Pathology/DNA Probes/Dose-Response RelationshipDrug/Drug ResistanceNeoplasm/Humans/Immunohistochemistry/Paclitaxel/RNAMessenger/genetics/ReceptorsProgesterone/physiologyindividualized chemotherapymedicine.diseaseAntineoplastic Agents PhytogenicImmunohistochemistryIn vitrochemosensitivityEndocrinologyOncologyPaclitaxelchemistryDrug Resistance NeoplasmCancer researchImmunohistochemistryTranslational TherapeuticsDNA ProbesReceptors ProgesteroneBreast carcinomabusinessBritish Journal of Cancer
researchProduct

Expression pattern of the urokinase-plasminogen activator system in rat DS-sarcoma: Role of oxygenation status and tumour size

2002

The urokinase plasminogen activator system plays a central role in malignant tumour progression. Both tumour hypoxia and enhancement of urokinase plasminogen activator, urokinase plasminogen activator-receptor and plasminogen activator inhibitor type 1 have been identified as adverse prognostic factors. Upregulation of urokinase plasminogen activator or plasminogen activator inhibitor type 1 could present means by which hypoxia influences malignant progression. Therefore, the impact of hypoxia on the expression pattern of the urokinase plasminogen activator system in rat DS-sarcoma in vivo and in vitro was examined. In the in vivo setting, tumour cells were implanted subcutaneously into rat…

Cancer Researchplasminogen activator inhibitor type-1DS-sarcomaEnzyme-Linked Immunosorbent AssayReceptors Cell Surfaceurokinase plasminogen activator receptorBiologyReceptors Urokinase Plasminogen Activatorchemistry.chemical_compoundDownregulation and upregulationIn vivoPlasminogen Activator Inhibitor 1Tumor Cells CulturedmedicineAnimalsExperimental TherapeuticsZymographyRNA Messengerurokinase plasminogen activatorHyperoxiaUrokinasehypoxiaReverse Transcriptase Polymerase Chain ReactionGene Expression ProfilingSarcomamalignant progressionUrokinase-Type Plasminogen ActivatorMolecular biologyIn vitroRatsGene Expression Regulation NeoplasticOxygenUrokinase receptorOncologychemistryOrgan SpecificityPlasminogen activator inhibitor-1medicine.symptommedicine.drugBritish Journal of Cancer
researchProduct

Beyond cholesterol reduction, the pleiotropic effects of statins: is their use in cancer prevention hype or hope?

2013

ISSN 1758-4299 10.2217/CLP.13.29 © 2013 Future Medicine Ltd Clin. Lipidol. (2013) 8(3), 273–277 Pleiotropic effects of statins Millions of patients worldwide are currently tak­ ing prescribed statins. Clinical trials have dem­ onstrated that statins reduce the risk of cardio­ vascular disease [1]. Statins are well known to reduce cholesterol levels through the inhibition of 3­hydroxy­methylglutaryl CoA reductase [2]. However, great interest has recently been paid to the mechanisms beyond cholesterol reduc­ tion (pleiotropic effects) by which statins exert their action. Indeed, statins are associated with plaque stabilization and improvement of endo­ thelial function, as well as anti­inflamm…

Cancer preventionIsoprenoid synthesisbusiness.industryCholesterolEndocrinology Diabetes and Metabolismnutritional and metabolic diseasesContext (language use)Pharmacologyanticancer drugs cancer chemotherapeutics statins tumorchemistry.chemical_compoundchemistryAntithromboticMedicinelipids (amino acids peptides and proteins)cardiovascular diseasesCardiology and Cardiovascular MedicinebusinessClinical Lipidology
researchProduct

Clinical Practice Guideline on Melanoma From the Spanish Academy of Dermatology and Venereology (AEDV)

2020

El diagnóstico y tratamiento del melanoma en atención especializada es un campo en el que se han producido numerosos cambios. El objetivo de esta guía es ofrecer a los dermatólogos españoles una referencia para resolver las dudas clínicas más frecuentes basándose en la evidencia actual. Para la realización de esta guía se escogió a miembros del Grupo Español de Dermato-Oncología y Cirugía con experiencia en el tratamiento de estos tumores y con interés en participar en la elaboración de la guía. Se hizo una adaptación de las guías de práctica clínica existentes mediante el método ADAPTE: inicialmente se resumió el proceso de atención y se elaboraron las preguntas clínicas relevantes. Se sel…

Care processmedicine.medical_specialtyPractice guidelineHistologyVenereologySkin NeoplasmsBiopsyTerapéuticaAntineoplastic AgentsDermatologyTherapeutics030204 cardiovascular system & hematologyPathology and Forensic MedicineHutchinson's Melanotic Freckle03 medical and health sciences0302 clinical medicineDiagnòsticDiagnosismedicineRelevance (law)HumansAgree ii030212 general & internal medicineNeoplasm MetastasisMelanomaNeoplasm StagingEvidence-Based Medicinebusiness.industrySentinel Lymph Node BiopsyDiagnósticoDisease ManagementGuidelineDiagnosis Diagnóstico Guía de práctica clínica Melanoma Practice guideline Terapéutica TherapeuticsTerapèuticaPatient preferenceDermatologyCombined Modality TherapyClinical PracticeGuía de práctica clínicaMolecular Diagnostic Techniquesbusiness
researchProduct

New neuroprotective effect of lemon integropectin on neuronal cellular model

2021

Lemon IntegroPectin obtained via hydrodynamic cavitation of organic lemon processing waste in water shows significant neuroprotective activity in vitro, as first reported in this study investigating the effects of both lemon IntegroPectin and commercial citrus pectin on cell viability, cell morphology, reactive oxygen species (ROS) production, and mitochondria perturbation induced by treatment of neuronal SH-SY5Y human cells with H2O2. Mediated by ROS, including H2O2 and its derivatives, oxidative stress alters numerous cellular processes, such as mitochondrial regulation and cell signaling, propagating cellular injury that leads to incurable neurodegenerative diseases. These results, and t…

Cell signalingantioxidantPhysiologyhesperidin;Antioxidant Flavonoids Hesperidin Mitochondria Neu-roprotective Neurological disease Oxidative stress PectinClinical BiochemistryRM1-950antioxidant;MitochondrionCell morphologymedicine.disease_causeBiochemistryNeuroprotectionArticleflavonoids;03 medical and health sciences0302 clinical medicinehesperidinmedicineoxidative stressViability assayneurological diseaseMolecular Biology030304 developmental biologychemistry.chemical_classificationpectinoxidative stress;neuroprotective;0303 health sciencesReactive oxygen speciespectin;neuroprotectiveCell BiologyCell biologymitochondriachemistryneurological disease;flavonoidsTherapeutics. PharmacologyCellular model030217 neurology & neurosurgeryOxidative stress
researchProduct

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

2020

Abstract Background Fibroblast activation protein (FAP) is a proline selective serine protease that is overexpressed in tumor stroma and in lesions of many other diseases that are characterized by tissue remodeling. In 2014, a most potent FAP-inhibitor (referred to as UAMC1110) with low nanomolar FAP-affinity and high selectivity toward related enzymes such as prolyl oligopeptidase (PREP) and the dipeptidyl-peptidases (DPPs): DPP4, DPP8/9 and DPP2 were developed. This inhibitor has been adopted recently by other groups to create radiopharmaceuticals by coupling bifunctional chelator-linker systems. Here, we report squaric acid containing bifunctional DATA5m and DOTA chelators relied on UAMC…

Computer. Automationlcsh:Medical physics. Medical radiology. Nuclear medicine540 Chemistry and allied sciencesPREPPharmacology. Therapylcsh:R895-920Gallium-68lcsh:RM1-950610 MedizinFAPDATA5mChemistrylcsh:Therapeutics. PharmacologyDOTA540 Chemie610 Medical sciencesSquaric acidneoplasmsEJNMMI Radiopharmacy and Chemistry
researchProduct

All-Atom simulations disclose how cytochrome reductase reshapes the substrate access/egress routes of its partner cyp450s

2020

Cytochromes P450 enzymes (CYP450s) promote the oxidative metabolism of a variety of substrates via the electrons supplied by the cytochrome P450 reductase (CPR) and upon formation of a CPR/CYP450 adduct. In spite of the pivotal regulatory importance of this process, the impact of CPR binding on the functional properties of its partner CYP450 remains elusive. By performing multiple microsecond-long all-Atom molecular dynamics simulations of a 520â »000-Atom model of a CPR/CYP450 adduct embedded in a membrane mimic, we disclose the molecular terms for their interactions, considering the aromatase (HA) enzyme as a proxy of the CYP450 family. Our study strikingly unveils that CPR binding alters…

CytochromeStereochemistryeducationPlasma protein binding-ReductaseMolecular Dynamics Simulation010402 general chemistry01 natural sciencesSubstrate SpecificityElectron Transport03 medical and health sciencesAromataseCytochrome P-450 Enzyme Systemhealth services administrationHumansddc:530General Materials Sciencecardiovascular diseasesP450 EnzymesPhysical and Theoretical Chemistryhealth care economics and organizations030304 developmental biologyNADPH-Ferrihemoprotein Reductase0303 health sciencesOxidative metabolismbiologyChemistrySubstrate (chemistry)Cytochrome P450 reductaseElectron transport chain0104 chemical sciencesAromatase; Cytochrome P-450 Enzyme System; Electron Transport; Humans; Molecular Dynamics Simulation; NADPH-Ferrihemoprotein Reductase; Protein Binding; Substrate SpecificitySettore CHIM/03 - Chimica Generale E Inorganicabiology.proteintherapeuticsProtein Binding
researchProduct

Microenvironmental adaptation of experimental tumours to chronic vs acute hypoxia

2004

This study investigated long-term microenvironmental responses (oxygenation, perfusion, metabolic status, proliferation, vascular endothelial growth factor (VEGF) expression and vascularisation) to chronic hypoxia in experimental tumours. Experiments were performed using s.c.-implanted DS-sarcomas in rats. In order to induce more pronounced tumour hypoxia, one group of animals was housed in a hypoxic atmosphere (8% O(2)) for the whole period of tumour growth (chronic hypoxia). A second group was acutely exposed to inspiratory hypoxia for only 20 min prior to the measurements (acute hypoxia), whereas animals housed under normal atmospheric conditions served as controls. Acute hypoxia reduced…

DNA ReplicationMaleCancer ResearchPathologymedicine.medical_specialtyBiologyperfusionRats Sprague-Dawleychemistry.chemical_compoundOxygen ConsumptionVascularityIn vivomedicineAnimalsExperimental TherapeuticshypoxiaCell growthDNA NeoplasmNeoplasms ExperimentalOxygenationHypoxia (medical)VEGFCell HypoxiaRatsVascular endothelial growth factorDisease Models AnimalKineticscell proliferationBlood pressureOncologychemistryvascularityAcute DiseaseChronic Diseaseoxygenationmedicine.symptomPerfusionCell DivisionBritish Journal of Cancer
researchProduct

Defensive strategies in a big obese group [MECCANISMI DI DIFESA IN UN GRUPPO DI PERSONE CON OBESITA']

2013

Aim. The aim of this study was to explore thè defense mechanisms of people with moderate and severe obesity. In fact, thè defensive structure is an effective predictor for thè best management of thè disease. Methods. 204 people (164 F-40 M) bave been recruited: 40 with BMI between 30 and 34.9, with moderate obesity, 36 with BMI between 35 and 39.9, with severe obesity, and 128 with BMI>40, with serious obesity, ali of them pertaining to thè clinic for obesity treatment at University Hospital of Palermo. Ali subjects were administered thè Defense Mechanisms Inventory (DMI), a type of reactive that explores defense mechanisms. The psychiatric comorbidity was excluded by thè DSM (SCIDI and II)…

Defence mechanismSettore M-PSI/08 - Psicologia ClinicaObesityTherapeuticsSettore MED/25 - PsichiatriaSettore MED/39 - Neuropsichiatria Infantile
researchProduct

Role of Myeloid-Epithelial-Reproductive Tyrosine Kinase and Macrophage Polarization in the Progression of Atherosclerotic Lesions Associated With Non…

2019

Recent lines of evidence highlight the involvement of myeloid-epithelial-reproductive tyrosine kinase (MerTK) in metabolic disease associated with liver damage. MerTK is mainly expressed in anti-inflammatory M2 macrophages where it mediates transcriptional changes including suppression of proinflammatory cytokines and enhancement of inflammatory repressors. MerTK is regulated by metabolic pathways through nuclear sensors including LXRs, PPARs, and RXRs, in response to apoptotic bodies or to other sources of cholesterol. Nonalcoholic fatty liver disease (NAFLD) is one of the most serious public health problems worldwide. It is a clinicopathological syndrome closely related to obesity, insuli…

Drug targeting0301 basic medicineMacrophageMacrophage polarizationInflammationReviewMonocyteProinflammatory cytokine03 medical and health sciencesMerTK0302 clinical medicineFibrosisNonalcoholic fatty liver diseasemedicineNonalcoholic fatty liver diseaseMacrophagePharmacology (medical)InflammationPharmacologybusiness.industrylcsh:RM1-950Lipid metabolismMERTKmedicine.diseasemacrophagesAtherosclerosis; Drug targeting; Inflammation; Macrophages; MerTK; Monocytes; Nonalcoholic fatty liver diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyAtherosclerosi030220 oncology & carcinogenesisCancer researchatherosclerosismedicine.symptommonocytesbusinessFrontiers in Pharmacology
researchProduct